About marstacimab
Tissue factor pathway inhibitor
Used for
- Prevention of bleeding episodes in people aged 12 years or older with severe haemophilia A or B, without inhibitors.
Usual adult dose
150 mg under the skin once weekly; some adults may use 300 mg once weekly if bleeding control is inadequate.
Usual dose in children
For ages 12–17: 150 mg under the skin once weekly; some may use 300 mg weekly if needed.
Common side effects
- Injection-site reactions
- Headache
- High blood pressure
- Blood clots
Important warnings
- May cause serious blood clots, especially with high doses of clotting-factor products.
- Not for treating an active bleed; use prescribed clotting-factor treatment.
- Avoid use in people with a history of blood clots unless a specialist recommends it.
- Do not use with other haemophilia medicines without specialist guidance.
Pregnancy
Human pregnancy information is limited. Use only if a clinician considers it necessary; discuss pregnancy plans with the haemophilia team.
Breastfeeding
It is unknown whether marstacimab passes into breast milk. A clinician should weigh treatment benefits against potential risks.
Interactions
- Clotting-factor concentrates and other haemostatic medicines may increase clot risk, particularly at high doses.
- Tell the haemophilia team about all medicines used to treat bleeding.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.